It was a rough day for a pair of small-cap biotech stocks and for chip giant Nvidia, though for very different reasons. Faeth Therapeutics and Abeona Therapeutics both slid after company-specific news, while Nvidia dropped after the company said it was opening an internal investigation tied to reports about CEO Jensen Huang.
Biotech swings: Faeth and Abeona
Small-cap biotechs are known for sharp moves because a single clinical trial update or pipeline decision can dramatically change the odds of future revenue. That volatility was on full display Tuesday.
Faeth Therapeutics said its phase 2 trial of a drug combination in advanced endometrioid endometrial cancer met some key measures: a 33% confirmed objective response rate and an 83% disease control rate. But the stock still plunged 43%, with trading volume far above normal. That suggests investors were looking beneath the headline numbers and didn't like what they saw—perhaps questioning the durability of responses, the size of the effect, or how the data compares to existing treatments.
Abeona Therapeutics also fell after a deal update. The company didn't provide specifics in the brief, but such moves often reflect concerns about financing, partnership terms, or the timeline for a product's commercial launch. For investors in small biotechs, the lesson is that headline results can be misleading, and the market's reaction is often more telling than the press release.
Nvidia: internal probe adds to pressure
Nvidia, the world's most valuable chipmaker and a bellwether for the AI trade, saw its shares drop after the company announced it was opening an internal probe related to reports about CEO Jensen Huang. The reports, which have been covered widely, allege a personal matter involving Huang. The company said it is looking into the situation.
This comes at a time when Nvidia is already under scrutiny. The company has faced a criminal probe from the Justice Department over its Megaspeed case, and the stock has been volatile as investors weigh the sustainability of AI-driven demand. The internal probe adds a layer of governance uncertainty to a company that is central to the broader market's AI optimism.
Nvidia's drop also weighed on the wider AI trade, as seen in Wall Street's rebound being tempered by the probe. The company's next earnings report is seen as a bigger test than regulatory issues, according to analysts, with supply constraints being the key limit on growth.
What it means for investors
For everyday investors, these moves highlight two different types of risk. In biotech, the risk is binary: a trial can succeed or fail, and the stock reacts accordingly. Even positive-sounding data can disappoint if the market expected more. That's why biotech stocks are often considered high-risk, high-reward investments, and why diversification is crucial.
For Nvidia, the risk is more about sentiment and governance. The company's fundamentals remain strong—it's still the dominant player in AI chips, and demand shows no sign of slowing. But news like an internal probe can shake investor confidence, especially when the stock trades at a high valuation. As RBC notes, supply is the limit, not demand.
Investors should also keep an eye on the broader market context. Nvidia's moves often drag the entire tech sector, and by extension the major indices, as seen in the recent session where oil fell 4% but Nvidia dropped 5%. That means even if you don't own Nvidia directly, its fortunes can affect your portfolio through index funds or ETFs.
For those watching the AI space, the probe is just one of several factors. Competition is heating up, with Google unveiling new TPU chips to challenge Nvidia, and the market is also watching for a potential Anthropic IPO as a test of AI sentiment. But for now, Nvidia's internal investigation is the immediate story, and investors will be watching for any updates on its findings.
In the end, both stories underscore the importance of looking beyond the headlines. For biotech, it's about reading the data and the market's reaction. For Nvidia, it's about separating noise from fundamentals. Neither is easy, but staying informed is the first step.
